Neuren Pharmaceuticals (CHIA:NEU) - Stock Price, News & Analysis

Resumen acción NEU

Neuren Pharmaceuticals Limited, empresa biofarmacéutica, desarrolla medicamentos para el tratamiento de trastornos neurológicos.

Acerca de la empresa

NEU fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	6/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 68.1% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 4.21%

Los beneficios aumentaron un 85270.1% el año pasado

Los analistas coinciden en que el precio de las acciones subirá un 39.3%

Análisis de riesgos

No se han detectado riesgos en NEU a partir de nuestros controles de riesgos.

Competidores de Neuren Pharmaceuticals Limited

Vitura Health

ASX:VIT

AU$109.4m

Probiotec

ASX:PBP

AU$233.8m

ECS Botanics Holdings

ASX:ECS

AU$28.3m

Vita Life Sciences

ASX:VLS

AU$135.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Neuren Pharmaceuticals
Historical stock prices
Current Share Price	AU$20.68
52 Week High	AU$25.90
52 Week Low	AU$10.02
Beta	1.99
1 Month Change	-1.57%
3 Month Change	-12.85%
1 Year Change	55.49%
3 Year Change	1,398.55%
5 Year Change	1,722.03%
Change since IPO	744.08%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	NEU	AU Pharmaceuticals	Mercado AU
7D	-0.7%	0.6%	0.9%
1Y	55.5%	44.5%	7.7%

Rentabilidad frente al sector: NEU superó al sector Australian Pharmaceuticals , que obtuvo un rendimiento del 10.2% el año pasado.

Rentabilidad vs. Mercado: NEU superó al mercado Australian, que obtuvo un rendimiento del -0.5% el año pasado.

Volatilidad de los precios

Is NEU's price volatile compared to industry and market?
NEU volatility
NEU Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.3%

Precio estable de las acciones: NEU no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NEU (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2001	n/a	Jon Pilcher	www.neurenpharma.com

Neuren Pharmaceuticals Limited, empresa biofarmacéutica, desarrolla medicamentos para el tratamiento de trastornos neurológicos. Su principal producto es la trofinetida, que se encuentra en fase III de ensayo clínico para el tratamiento del síndrome de Rett, y ha completado la fase II de ensayo clínico para tratar el síndrome X frágil. La empresa desarrolla el NNZ-2591, que ha completado el ensayo clínico de fase I para el tratamiento de los síndromes de Phelan-McDermid, Angelman, Pitt Hopkins y Prader-Will.

Resumen de fundamentos de Neuren Pharmaceuticals Limited

¿Cómo se comparan los beneficios e ingresos de Neuren Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de NEU
Capitalización bursátil	AU$2.65b
Beneficios(TTM)	AU$157.08m
Ingresos (TTM)	AU$231.94m

16.8x

Ratio precio-beneficio (PE)

11.4x

Ratio precio-ventas (PS)

¿Está NEU sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NEU
Ingresos	AU$231.94m
Coste de los ingresos	AU$26.75m
Beneficio bruto	AU$205.19m
Otros gastos	AU$48.11m
Beneficios	AU$157.08m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	1.23
Margen bruto	88.47%
Margen de beneficio neto	67.72%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado NEU a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción NEU

Recompensas

Análisis de riesgos

Competidores de Neuren Pharmaceuticals Limited

ASX:VIT

AU$109.4m

ASX:PBP

AU$233.8m

ASX:ECS

AU$28.3m

ASX:VLS

AU$135.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Investor sentiment improves as stock rises 38%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 25% undervalued after recent price drop

Recent updates

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Investor sentiment improves as stock rises 38%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 25% undervalued after recent price drop

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

New 90-day low: AU$1.26

Full year 2020 earnings released: AU$0.086 loss per share (vs AU$0.11 loss in FY 2019)

Independent Non-Executive Chairman recently bought AU$50k worth of stock

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

New 90-day high: AU$1.40

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

New 90-day high: AU$1.30

New 90-day low: AU$1.06

New 90-day low: AU$1.10

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Neuren Pharmaceuticals Limited

16.8x

11.4x

Beneficios e Ingresos